Syros Pharmaceuticals, Inc. - common stock (SYRS): Price and Financial Metrics
Syros Pharmaceuticals, Inc. - common stock (SYRS)
Today's Latest Price: $10.44 USD
Updated Jan 27 4:00pm
Add SYRS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
SYRS Stock Summary
- With a one year PEG ratio of 4,997.78, Syros Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 99.18% of US stocks.
- SYRS's price/sales ratio is 52.41; that's higher than the P/S ratio of 94.41% of US stocks.
- As for revenue growth, note that SYRS's revenue has grown 318.38% over the past 12 months; that beats the revenue growth of 97.81% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Syros Pharmaceuticals Inc are CNCE, AGIO, CMRX, DRNA, and ALPN.
- Visit SYRS's SEC page to see the company's official filings. To visit the company's web site, go to www.syros.com.
SYRS Stock Price Chart Interactive Chart >
SYRS Price/Volume Stats
| Current price | $10.44 | 52-week high | $15.65 |
| Prev. close | $11.33 | 52-week low | $4.26 |
| Day low | $10.23 | Volume | 797,733 |
| Day high | $11.35 | Avg. volume | 913,718 |
| 50-day MA | $10.68 | Dividend yield | N/A |
| 200-day MA | $10.14 | Market Cap | 586.70M |
Syros Pharmaceuticals, Inc. - common stock (SYRS) Company Bio
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company was founded in 2011 and is based in Cambridge, Massachusetts.
Loading social stream, please wait...